Disease Context and Molecular Target Landscape

Hepatocellular carcinoma is the fifth most common cancer globally and the second leading cause of cancer-related death, with incidence rising across North America, Latin America, and Central Europe. Its etiologies span infectious drivers — hepatitis B virus (HBV) and hepatitis C virus (HCV) — and non-infectious contributors including non-alcoholic steatohepatitis (NASH), NAFLD, and alcoholic liver disease. This dual epidemiology has shaped a target landscape that spans viral immune suppression, metabolic inflammation, and tumor-intrinsic oncogenic signalling.

The foundational molecular target in HCC is the VEGFR axis. Sorafenib — a multitargeted tyrosine kinase inhibitor (TKI) acting on VEGFR1, VEGFR2, VEGFR3, PDGFRβ, and Raf family kinases — was approved as first-line standard of care for unresectable HCC in 2008, establishing anti-angiogenesis as the primary treatment architecture for over a decade. Bayer Healthcare LLC holds multi-jurisdictional patents (WO, US, CA, EP, JP) covering sorafenib-associated biomarker signatures, explicitly identifying soluble VEGFR-2 (sVEGFR-2), VEGF, and HGF as pharmacodynamic biomarkers for sorafenib monitoring in HCC patients.

Immune regulatory targets have since emerged as equally critical. According to WIPO-indexed patent filings, the dominant immune checkpoint targets in HCC include PD-1/PD-L1, LAG-3, TIGIT, and CXCR2. LAG-3 (lymphocyte activation gene-3) functions as a co-inhibitory molecule on T cells, contributing to immune exhaustion within the HCC tumor microenvironment. PD-1/PD-L1 is the central axis across records from Bristol-Myers Squibb, Regeneron Pharmaceuticals, Genentech, and Roche. TIGIT is identified by Roche/Genentech as an additional co-inhibitory checkpoint of interest. CXCR2 — a neutrophil chemokine receptor — is highlighted in academic literature as a target enabling immunotherapy sensitization specifically in NASH-driven HCC.

Additional targets identified in retrieved records include claudin-1 — a tight junction protein targeted by anti-claudin-1 antibodies from INSERM and Université de Strasbourg for sorafenib- and PD-1–resistant HCC — and EpCAM and osteopontin (OPN), earlier-stage targets in US government-assigned patents for HCC metastasis suppression. HDAC inhibitors appear as ADC payloads in an Alfasigma patent with claimed utility across solid tumours including HCC.

Checkpoint Combination Strategies: LAG-3, PD-1, and Beyond

The most heavily represented therapeutic modality in this patent dataset is dual immune checkpoint blockade targeting both LAG-3 and PD-1 simultaneously in HCC — a strategy led almost exclusively by Bristol-Myers Squibb. BMS has filed at least seven distinct patent records covering methods of treating HCC with a LAG-3 antagonist (anti-LAG-3 antibody, relatlimab) alone or combined with an anti-PD-1 antibody (nivolumab), spanning jurisdictions including the US, CA, AU, IN, IL, SG, and CN.

The specificity of dosing regimens disclosed — 480 mg anti-LAG-3 antibody co-administered with 480 mg anti-PD-1 antibody as first-line therapy for unresectable or metastatic HCC — signals that these regimens reflect active clinical investigation rather than early-stage exploratory filings. The BMS portfolio extends beyond dual blockade: a distinct cluster of at least four records (CA, AU, WO, US jurisdictions, filed 2023–2025) proposes a three-agent regimen combining a LAG-3 antagonist, a PD-1 pathway inhibitor, and an anti-angiogenesis agent for HCC.

“Bristol-Myers Squibb holds at least 10 patent records across US, CA, AU, IL, IN, SG, CN, and WO jurisdictions — the most concentrated HCC-specific IP position in this dataset — all focused on LAG-3 antagonism alone or in combination for hepatocellular carcinoma.”

Genentech and Roche describe a mechanistically distinct triple combination strategy: PD-1 axis binding antagonist (atezolizumab, anti-PD-L1) plus VEGF antagonist (bevacizumab) plus anti-TIGIT antagonist antibody (tiragolumab). A 2024 Genentech WO filing introduces tobemstomig — a bispecific antibody targeting both PD-1 and LAG-3 simultaneously — combined with bevacizumab. This bispecific format represents a structural simplification relative to two-antibody LAG-3/PD-1 combinations, with implications for clinical complexity, dosing logistics, and IP protection strategy.

Regeneron Pharmaceuticals has filed patents in IL and CN jurisdictions covering neoadjuvant use of cemiplimab (anti-PD-1) for HCC, followed by surgical resection and optional post-surgery adjuvant administration. This signals an extension of checkpoint therapy into earlier, potentially curative-intent settings — a clinical paradigm requiring IND-enabling or active trial status. Predictive biomarkers for checkpoint response in liver cancer include CD8+ T cell populations identified by markers including CXCR3, CD45RO, CCR7, CD8, and HLADR, according to a Singapore Health Services patent.

VEGFR and Anti-Angiogenesis: From Standalone TKI to Combination Partner

The role of VEGFR-targeted therapy in HCC has undergone a structural shift: what began as standalone multi-kinase inhibition with sorafenib has evolved into an essential combination partner within checkpoint-based regimens. Sorafenib’s mechanism — inhibiting VEGFR1, VEGFR2, VEGFR3, PDGFRβ, and C-Raf — established the biological rationale for anti-angiogenesis in HCC from its 2008 approval for unresectable disease. Retrieved results now show VEGF antagonism being incorporated as a combination partner with checkpoint inhibitors rather than as standalone therapy.

The atezolizumab plus bevacizumab (“T+A”) combination — referenced in a Nanjing Drum Tower Hospital CN patent — is described with published data indicating a 42% reduction in death risk versus sorafenib in advanced HCC. This established backbone is now being extended: Roche/Genentech records describe tiragolumab (anti-TIGIT) being added to atezolizumab and bevacizumab as a third immune checkpoint co-blockade layer. According to NIH-published oncology literature, combining angiogenesis inhibition with immune checkpoint blockade can normalize the tumour vasculature and improve T cell infiltration — providing a mechanistic rationale for these multi-agent architectures.

Lenvatinib, an additional VEGFR-targeting TKI, is referenced in CN patent records from Nanjing Drum Tower Hospital as part of multi-agent combinations for hepatobiliary cancers. A Fudan University Zhongshan Hospital CN patent describes gemcitabine plus oxaliplatin plus lenvatinib plus anti-PD-1 as a combination for intrahepatic cholangiocarcinoma, with single-cell transcriptomics identifying CD8_GZMB and Macro_CD5L subpopulations as predictive biomarkers — illustrating the breadth of multi-agent combinatorial approaches being applied to hepatobiliary cancers broadly.

ADC Platforms and Emerging Resistance-Focused Targets

Beyond checkpoint and VEGFR strategies, the HCC pipeline contains several earlier-stage modalities targeting treatment resistance and underserved patient subpopulations — including HDAC inhibitor-based antibody-drug conjugates, anti-claudin-1 antibodies for drug-resistant disease, and CXCR2 inhibition for NASH-specific HCC.

HDAC Inhibitor-Based ADCs

Alfasigma S.p.A. holds a PCT patent (WO 2018/178060) covering antibody-drug conjugates in which HDAC inhibitors serve as the cytotoxic payload, with claimed utility in cancer therapy (A61P 35/00) including potential HCC applications. The mechanistic rationale is delivery of HDAC-inhibiting activity via antibody targeting to tumour cells, potentially improving tumour selectivity relative to systemic HDAC inhibitor administration. No HCC-specific clinical signal is present in the retrieved text for this asset. Standards for ADC development and payload assessment are tracked by bodies including the EMA, which has published guidance on complex biological medicinal products.

Anti-Claudin-1 Antibodies for Drug-Resistant HCC

INSERM and Université de Strasbourg records describe anti-claudin-1 monoclonal antibodies for HCC treatment specifically in patients with sorafenib and/or PD-1 antagonist (nivolumab) resistance. The mechanism involves direct action on oncogenic signalling pathways independent of anti-viral activity. Claudin-1 is a tight junction protein that functions as a direct oncogenic signalling target in HCC — a mechanistically distinct approach from checkpoint or kinase inhibition. These assets are classified at the preclinical-to-translational stage, with patents filed in US, WO, EP, and CN jurisdictions.

CXCR2 Inhibition for NASH-HCC Immunotherapy Sensitization

A 2022 academic paper from Newcastle University Centre for Cancer provides experimental evidence that CXCR2 inhibition with a small molecule antagonist sensitizes NASH-HCC to anti-PD-1 therapy in murine NASH-HCC models. The mechanism involves modulation of neutrophil infiltration, characterised by imaging mass cytometry, RNA-seq, and flow cytometry. CXCR2 — a neutrophil chemokine receptor — mediates immunotherapy resistance in the NASH-HCC subtype, which may respond poorly to conventional immune checkpoint inhibitor therapy. This represents a preclinical, literature-driven signal; no human trial data is present in this record.

“The CXCR2 academic data and the broader absence of NASH-specific IP in this dataset signal a gap between biological understanding and IP coverage — a potential white space for early filing activity in NASH-HCC immunotherapy sensitization.”

EpCAM and osteopontin (OPN) are identified in earlier-stage US government-assigned patents (U.S. Department of Health and Human Services) as therapeutic targets for HCC metastasis suppression via antibody or antisense/siRNA approaches. HLA-DR+ tumour cells are identified in a Henan Provincial People’s Hospital 2025 CN filing as predictive biomarkers for checkpoint response in liver cancer — contributing to the patient stratification toolkit alongside the CD8+ T cell markers described in the Singapore Health Services patent.

Assignee IP Landscape and Strategic Implications

The HCC patent dataset is dominated by commercial biopharma entities, with academic literature contributions fewer in number but mechanistically informative. Understanding the assignee landscape is essential for freedom-to-operate analysis, white-space identification, and competitive intelligence — areas where patent data published through organisations such as the EPO provides structured, jurisdiction-level visibility.

Bristol-Myers Squibb is the most active single assignee in this dataset, with at least 10 patent records across eight jurisdictions — all focused on LAG-3 antagonism alone or in combination for HCC. This represents the most concentrated HCC-specific IP position in the dataset. Any entrant seeking to develop competing LAG-3-based HCC therapies will need to navigate this IP position carefully.

Genentech holds at least two patent records covering PD-L1/VEGF/TIGIT triple combination and bispecific antibody approaches for liver cancer. Hoffmann-La Roche contributes a CN-jurisdiction patent on anti-TIGIT treatment (tiragolumab plus atezolizumab plus/minus bevacizumab). Bayer Healthcare LLC holds multi-jurisdictional patents covering sorafenib-associated biomarker signatures — predominantly preclinical/translational biomarker IP rather than novel drug mechanism claims. INSERM and Université de Strasbourg hold multiple US, WO, and EP patents on HCC cell models and anti-claudin-1 antibody therapy, representing European academic-to-biotech translation activity.

The strategic implications that follow from this IP landscape are significant. The bispecific antibody format — exemplified by tobemstomig (anti-PD-1/LAG-3) combined with bevacizumab in Genentech’s 2024 WO filing — may compress future HCC treatment regimens by reducing the number of agents required in combination, carrying implications for clinical complexity, IP protection, and commercial pricing dynamics. Meanwhile, NASH-HCC as an immunotherapy-resistant subtype represents an underserved opportunity: the CXCR2 academic data and the broader absence of NASH-specific IP in this dataset signal a gap between biological understanding and IP coverage — a potential white space for early filing activity. Resistance-focused targeting of claudin-1 and CXCR2 signals a second-line and beyond opportunity in a commercially relevant and clinically underserved niche with limited current IP competition visible in this dataset.